{"prompt": "['Radiation therapy', 'Live vaccines within 30 days prior to the first dose of study treatment and while', 'participating in the study. Examples of live vaccines include, but are not limited to,', 'the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG,', 'and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed', 'virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,', 'FluMistR) are live attenuated vaccines and are not allowed.', 'Systemic glucocorticoids for any purpose other than to modulate symptoms from an', 'event of clinical interest of suspected immunologic etiology. The use of physiologic', 'doses of corticosteroids may be approved after consultation with the Sponsor.', 'Note: Inhaled steroids are allowed for management of asthma or seasonal', 'allergies.', 'Participants should avoid drugs that are known to prolong the QTc interval until the study', 'treatment has been discontinued, although these agents are not specifically prohibited if there', 'is a clinical indication for their use as long as the QTc has been < 480 ms as per monitoring', 'based on the Trial Flow Chart (Section 6.0).', 'Participants who, in the assessment by the investigator, require the use of any of the', 'aforementioned treatments for clinical management should be removed from the study. All', \"treatments that the Investigator considers necessary for a participant's welfare may be\", 'administered at the discretion of the Investigator in keeping with the community standards of', 'medical care.', 'Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed', 'during the ongoing study. If there is a clinical indication for any medication or vaccination', 'specifically prohibited during the study, discontinuation from study therapy or vaccination', 'may be required. The final decision on any supportive therapy or vaccination rests with the', \"investigator and/or the participant's primary physician. However, the decision to continue\", 'the participant on study treatment requires the mutual agreement of the investigator, the', 'Sponsor and the participant.', 'There are no prohibited therapies during the Long-Term Follow-Up Phase.', '5.5.3 Rescue Medications & Supportive Care', 'Participants should receive appropriate supportive care measures as deemed necessary by the', 'treating investigator. Suggested supportive care measures for the management of AEs with', 'potential immunologic etiology are outlined along with the dose modification guidelines in', 'Section 5.2.3.1, [Table 6]. Where appropriate, these guidelines include the use of oral or IV', 'treatment with corticosteroids, as well as additional anti-inflammatory agents if symptoms do', 'not improve with administration of corticosteroids. Note that several courses of steroid', 'tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For', 'each disorder, attempts should be made to rule out other causes such as metastatic disease or', '33']['bacterial or viral infection, which might require additional supportive care. The treatment', 'guidelines are intended to be applied when the Investigator determines the events to be', 'related to pembrolizumab.', 'Note: If after the evaluation of the event, it is determined not to be related to pembrolizumab,', 'the Investigator does not need to follow the treatment guidance.', 'It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or', 'skin photography as part of evaluation of the event.', '5.6', 'Participant Withdrawal/Discontinuation Criteria', 'Participants may discontinue study treatment at any time for any reason or be dropped from', 'the study treatment at the discretion of the investigator should any untoward effect occur. In', 'addition, a participant may be discontinued from study treatment by the investigator or the', 'Sponsor if study treatment is inappropriate, the trial plan is violated, or for administrative', 'and/or other safety reasons. Specific details regarding procedures to be performed at study', 'treatment discontinuation are provided in Section 7.1.5.1 (Other Procedures).', 'A participant must be discontinued from study treatment but continue to be monitored in the', 'study for any of the following reasons:', \"The participant or participant's legally acceptable representative requests to\", 'discontinue study treatment', 'Confirmed radiographic disease progression outlined in Section 7.1.4.1.4.', 'Any progression of any malignancy, or any occurrence of another malignancy that', 'requires active treatment', 'Unacceptable adverse experiences as described in 5.2.2.2 (lenvatinib) and 5.2.3.1', '(pembrolizumab).', 'The participant has a medical condition or personal circumstance which, in the', 'opinion of the investigator and/or sponsor, placed the participant at unnecessary risk', 'from continued administration of study treatment.', 'The participant has a confirmed positive serum pregnancy test', 'Sexually active subjects of childbearing potential who refuse to use medically', 'accepted barrier methods of contraception (e.g. male condom) during the course of', 'the study and for 4 months after discontinuation of study treatment', 'Noncompliance with study treatment or procedure requirements', 'Recurrent Grade 2 pneumonitis', 'The participant is lost to follow-up', '34']\n\n###\n\n", "completion": "END"}